Synlogic Appoints Lisa Kelly-Croswell to its Board of Directors

Joint Team from MIT and Synlogic Named a Biotechnology Grand Challenge Winner by Air Force Research Laboratory

Synlogic Outlines Upcoming Clinical Milestones

Synlogic Announces Advancement of SYNB1891 to Combination Arm Dosing with PD-L1 Checkpoint Inhibitor in the on-going Phase 1 Study for the Treatment of Solid Tumors and Lymphoma

Synlogic Appoints Michael Heffernan to its Board of Directors

Synlogic Presents SYNB8802 for Enteric Hyperoxaluria at the American Institute of Chemical Engineers Conference on Microbiome Engineering

Synlogic to Present at Upcoming Virtual Banking Conference

Synlogic Reports Third Quarter 2020 Financial Results and Provides Business Update

Synlogic Initiates Phase 1 Study of SYNB8802 for the Treatment of Enteric Hyperoxaluria

Synlogic Announces Third Quarter 2020 Conference Call & Webcast

Synlogic Presents Preclinical Data on SYNB8802 for Enteric Hyperoxaluria at American Society of Nephrology (ASN) Kidney Week 2020

Synlogic Appoints David Hava, Ph.D., as Chief Scientific Officer